[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371226-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371226-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pan-cancer-analysis-identifies-ykt6-as-a-prognostic-and-immunotherapy-biomarker-with-an-emphasis-on-cervical-cancer","Pan-Cancer Analysis Identifies YKT6 as a Prognostic and Immunotherapy Biomarker - with an Emphasis on Cervical Cancer","","Pan-cancer bioinformatics and experimental validation are used to evaluate YKT6 as a prognostic marker and immunotherapy-related biomarker, focusing on cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC). YKT6 expression patterns are correlated with pathological stage, survival, tumor microenvironment scores, and immune infiltration using TCGA-based analyses and multiple computational tools. Genomic alterations and epigenetic regulation are assessed, while q-PCR, TMA staining, and siRNA assays confirm tumor-promoting effects in CESC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pan-cancer-analysis-identifies-ykt6-as-a-prognostic-and-immunotherapy-biomarker-with-an-emphasis-on-cervical-cancer/371226/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-identifies-ykt6-as-a-prognostic-and-immunotherapy-biomarker-with-an-emphasis-on-cervical-cancer/371226.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main goal regarding YKT6?","Question",{"text":63,"@type":64},"To determine whether YKT6 has prognostic value and potential immunological functions, using pan-cancer analysis with emphasis on cervical cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets and tools were used to analyze YKT6?",{"text":68,"@type":64},"Analyses used TCGA, CCLE, and GTEx for expression associations, then ImmuCellAI, UCSC Xena, and the ESTIMATE algorithm for tumor microenvironment and immune infiltration relationships.",{"name":70,"@type":61,"acceptedAnswer":71},"How were the findings validated in cervical cancer?",{"text":72,"@type":64},"The cancer-promoting role of YKT6 in CESCs was validated using q-PCR, TMA staining, and siRNA assays, showing that YKT6 knockdown inhibited cervical cancer cell proliferation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371226,1790319826,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","OncoTargets and Therapy  \nOpen Access Full Text Article ORIGINAL RESEARCH  \nPan-Cancer Analysis Identifies YKT6 asa Prognostic and Immunotherapy Biomarker, with an Emphasis on Cervical Cancer  \nJiamin Liu, Qiang Zhang, Ling He, Huangyu Hu , Yixuan Wang, Ping Xie   \nDepartment of Gynecology, Sichuan Provincial Hospital of Traditional Chinese Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of China  \nCorrespondence: Ping Xie, Department of Gynecology, Sichuan Provincial Hospital of Traditional Chinese Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39, Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan Province, 610000, People’s Republic of China,  \nEmail [1044126054@qq.com](1044126054@qq.com)  \n\n| Background: Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)-mediated membrane fusion is crucial for autophagy, making YKT6, a key modulator of cell membrane fusion, a potential target for cancer therapy. However, its oncogenic role across different cancers remains unclear. This study was to investigate the prognostic value and potential immunological functions of YKT6, including cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) .\u003Cbr>Methods: Multiple bioinformatics databases, including The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE), and Genotype-Tissue Expression (GTEx) databases, were used to investigate the correlation of the YKT6 expression pattern with the pathological stage and survival rate across cancers. Furthermore, ImmuCellAI, the UCSC Xena platform, and the ESTIMATE algorithm were subsequently utilized to explore the potential relationship between YKT6 expression, the tumor microenvironment, and tumor immune infiltration. Profiling of YKT6 gene mutation and amplification, methylation, and copy number alteration (CNA) was performed on the basis of the TCGA database. Moreover, q-PCR, TMA staining, and siRNA assays were used to validate the cancer-promoting role of YKT6 in CESCs.\u003Cbr>Results: Our results reveal that YKT6 is a potential prognostic and cancer immunity biomarker. Elevated YKT6 expression is correlated with poor overall survival (OS) and disease-free survival (DFS) . Distinct gene mutation, methylation, and CNA patterns for YKT6 were found in certain types of cancers. The correlation of YKT6 expression with tumor-infiltrating immune cells was verified by analyzing the StromalScore, ESTIMATEScore, ImmuneScore, and tumor purity. In vitro analysis confirmed that YKT6 was highly expressed in advanced-grade CESCs and that the knockdown of YKT6 inhibited the proliferation of cervical cancer cells. Conclusion: The SNARE protein YKT6 serves as a biomarker and candidate oncogene with actionable mutations. Moreover, YKT6 has the potential to be a prognostic indicator in CESCs. Targeting YKT6 could enhance autophagy regulation and improve therapeutic strategies for personalized cancer treatment.\u003Cbr>Keywords: YKT6, pan-cancer analysis, CESC, TCGA, immune infiltration |\n| --- |\n| Introduction\u003Cbr>The morbidity and mortality rates of cancer are increasing worldwide.1 Scientists and researchers focusing on global public health have also become increasingly aware of this problem. Thus, therapeutic tumor vaccines, which can prevent an infection that might lead to cancer, are strongly recommended for adolescents. For example, the human papillomavirus (HPV) vaccine is usually employed to prevent HPV infection and HPV-associated cancers.2 However, in accordance with the latest cancer statistics from 2023, the incidence of advanced-stage cervical cancer and cervical adenocarcinoma, which are often undetected by cytology, continues to increase among young women.1 In principle, because HPV plays a significant role in the development of these cancers, the immune system is expected to eliminate HPV-induced tumors relatively quickly. However, these HPV-associated tumor","cbCaihcSeP4wkKfW","https://ap.wps.com/l/cbCaihcSeP4wkKfW","pdf",22863889,21,"English","# Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Autophagy and SNARE proteins\n## Immunotherapy context","[{\"question\":\"What is the study’s main goal regarding YKT6?\",\"answer\":\"To determine whether YKT6 has prognostic value and potential immunological functions, using pan-cancer analysis with emphasis on cervical cancer.\"},{\"question\":\"Which datasets and tools were used to analyze YKT6?\",\"answer\":\"Analyses used TCGA, CCLE, and GTEx for expression associations, then ImmuCellAI, UCSC Xena, and the ESTIMATE algorithm for tumor microenvironment and immune infiltration relationships.\"},{\"question\":\"How were the findings validated in cervical cancer?\",\"answer\":\"The cancer-promoting role of YKT6 in CESCs was validated using q-PCR, TMA staining, and siRNA assays, showing that YKT6 knockdown inhibited cervical cancer cell proliferation.\"}]","Pan-Cancer Analysis Identifies YKT6 as a Prognostic and Immunotherapy Biomarker - with an Emphasis on Cervical Cancer | PDF",1790191565,53,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84bd52bc3a0b35ef048210887b9198ba.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bdec37e3f801c792c464da8fc988845.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/526969039f9634065d0f62664e81cc4b.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c141ddfef43a06be9ceeba33be41d99b.webp",980,1268]